Salute e Benessere

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925…

CVC Brings Resources and Expertise to Further Develop and Commercialize Therakos CVC Brings Resources and Expertise to Further Develop and Commercialize Therakos DUBLINandLUXEMBOURG,Aug. 5, 2024/PRNewswire/ -- Mallinckrodt plc (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, and CVC Capital Partners ("CVC"), one of the world's leading investment firms, today announced that they have entered into a definitive agreement 1 under which CVC…

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical…

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “His leadership experience, track record in immuno-oncology drug development, and insights into biomarker development will prove invaluable as we continue to advance our pipeline. We look forward to the integral role he will play in shaping our...

Buyback of Class B shares in Essity during week 31, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...

Global Healthcare Supplies Industry To Witness Significant Growth In the…

The global advanced wound care market was estimated at USD 10.77 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.75% from 2024 to 2030. The demand for advanced wound care products is increasing owing to the rising prevalence of chronic diseases worldwide. The increasing geriatric population, which has slow healing capabilities, is expected to propel market growth. The global advanced wound care market was estimated atUSD 10.77 billionin 2023 and is...

Incontinence: TENA thinks it's time to talk about it

Bladder weakness, more common than you think Bladder weakness, more common than you think Around the world, over 200 million people experience or have experienced incontinence. More common than you'd think, the symptom affects 1 in 5 people over the age of 35 inCanada *, whereas it's often mistakenly thought that it's uniquely older people who experience bladder weakness. According to Google Trends, searches related to incontinence have increased by 500% in the last year alone...

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2024

Accumulated revenue for January – July 2024 increased by 19 % to SEK 1131.2 (952.0) million. Accumulated revenue for January –July 2024increased by 19 % toSEK 1131.2(952.0) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West Europe :...

Nanoflex Robotics Appoints Per Vegard Nerseth, Former CMR Surgical CEO, as…

Per Vegard brings over three decades of global business experience, including developing high-performing teams and launching new ventures in the robotics sector. Most recently, Per Vegard was the CEO of CMR Surgical, where he also served on the Board. Prior to CMR Surgical, Per Vegard held multiple portfolios at ABB, where he steered business lines' turnarounds and optimized for long-term strategic growth.Per Vegard's track record of navigating complex markets and scaling cutting-edge...

Philips to repurchase shares for up to EUR 125 million to cover long-term…

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase shares for an amount of up to EUR 125 million to cover certain of its obligations arising from its long-term incentive plans. At the current share price, this represents a total of approximately 4.8 million shares.The repurchases will be executed through a combination of forward transactions and open market purchases with a financial institution. Philips expects to take delivery...

BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111Launched updated variant-adapted COVID-19 vaccine in the European Union(“EU”), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application (“sBLA”) with the United States Food and Drug Administration (“U.S. FDA”)Reiterates guidance for total revenues in the range of €2.5-3...

Genmab Takes Full Control of Acasunlimab Development Program

Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreementThe overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that it will assume sole responsibility for the...

Skanray Partners with Tata Elxsi to Advance Surgical Imaging and Healthcare…

Tata Elxsi will lead a software platform-led approach to diagnostics that will support all imaging, critical care and surgical systems from the Skanray family, ensuring interoperability, compatibility and multi-modal functionality. This platform will also incorporate the latest technologies and process efficiencies from AI and GenAI. Tata Elxsi will lead a software platform-led approach to diagnostics that will support all imaging, critical care and surgical systems from the Skanray family,...

Immunovia Publishes Interim Report for January-June 2024

Significant events after the period Significant events after the period CEO's comments The second quarter of 2024 was highly productive, as we moved quickly to deliver key results, which include: 1. Finalized development of our high-performance test to detect early-stage pancreatic cancer 2. Established our new lab, which is now fully operational, in record time 3. Secured shareholder approval for a rights issue to fund the company through completion of the...

Immunovia's next-generation test to be included in large study of pancreatic…

The study will assess the use of biomarker tests to detect pancreatic cystic neoplasms (PCNs, or pancreatic cysts) that develop into pancreatic cancer. The overall clinical program will consist of three complementary studies: The study will assess the use of biomarker tests to detect pancreatic cystic neoplasms (PCNs, or pancreatic cysts) that develop into pancreatic cancer. The overall clinical program will consist of three complementary studies: The first study should be completed in 2025;...

EUROAPI - Availability of 2024 Half-Year Financial Report

Paris, 05 August, 2024 –EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI's website:https://www.euroapi.com/en/investors/regulatory-information/financial-reports.This report includes notably the 2024 half-year management report, the consolidated financial statements on 30 June 2024, and the Statutory Auditors' review report on the...

Invitation to the presentation of Calliditas´s interim report January - June…

The presentation will be given in English. The presentation will be given in English. Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50049712 After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity...

NTG Nordic Transport Group acquires SCHMALZ+SCHÖN Holding GmbH

Company announcement no. 6 – 24 2 August 2024 NTG Nordic Transport Groupacquires SCHMALZ+SCHÖN Holding GmbH NTG Germany GmbH (“NTG”), a fully owned subsidiary of NTG Nordic Transport Group A/S, has signed an agreement to acquire 100% of the shares in German-based SCHMALZ+SCHÖN Holding GmbH (“SSH”).Founded in 1959, SSH specialises in road and logistics services, offering tailored solutions to complex challenges for its long-standing customer base. Known for high quality and...

Information regarding the total number of voting rights and total number of…

Information regarding the total number of voting rights andtotal number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 07/31/2024 96,498,927 Total gross of voting rights: 96,498,927 Total net* of voting rights: 96,214,457 * Net total = total...

Casino Group: Release of the H1 2024 financial report

RELEASE OF THE HALF YEAR 2024FINANCIAL REPORT The Group has released its half year 2024 financial report, in English, on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2024/08/H1-2024-Financial-Report.pdfAnalyst and investor contactsChristopher Welton +33 (0)1 53 65 64 17cwelton.exterieur@groupe-casino.fr Charlotte Izabel +33 (0)1 53 70 51 29 cizabel@groupe-casino.frInvestor Relations +33 (0)1...

The Department of Health - Abu Dhabi provides gene therapy for Duchenne Muscular…

While previously the therapy was accessible only inthe United States, this groundbreaking treatment will now also be offered atSheikh Khalifa Medical City (SKMC), part of SEHA; a subsidiary of PureHealth, further cementingAbu Dhabi'sposition as a leading healthcare destination and life sciences hub globally. The treatment was approved by the U.S. Food and Drug Administration (FDA) inJune 2023, and it was administered to an Emirati DMD patient by a specialist team led by a...

Pharmaceutical Contract Manufacturing Market worth $319.6 billion by 2029 driven…

Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" Browse in-depth TOC on "Pharmaceutical Contract Manufacturing Market" 148 - Tables60 - Figures415 - Pages Thermo Fisher Scientific, Inc.: Market Leader in Pharmaceutical Contract Manufacturing Thermo Fisher Scientific, Inc. stands as a dominant force in the pharmaceutical contract manufacturing market, holding the largest market share in 2023. The company excels with a comprehensive suite of...

Facial Injectables Market Poised to Reach US$ 37.1 Billion by 2031, Driven by…

Penetration of Social Media Responsible for Bright Facial Injectables Market Outlook Penetration of Social Media Responsible for Bright Facial Injectables Market Outlook Facial injectables are commonly used on nasolabial folds, cheekbones, and lips. For instance, dynamic wrinkles caused by different movements are minimized by injecting botulinum toxin, often known as Botox, into the face's muscles. Rise in popularity of social media is a key factor fostering market expansion. A large...

Diabetes Supplements Market to Reach USD 13.4 billion by 2031, Growth at CAGR…

Research states that cinnamon, chromium, or berberine is likely of helping with controlling blood sugar. It further states that alpha-lipoic acid may also help in reduction of pain linked with diabetic neuropathy (nerve-related problems). Research states that cinnamon, chromium, or berberine is likely of helping with controlling blood sugar. It further states that alpha-lipoic acid may also help in reduction of pain linked with diabetic neuropathy (nerve-related problems). Request a PDF...

Unit dose packaging Market worth $43.8 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Unit dose packaging Market". Browse in-depth TOC on "Unit dose packaging Market". 165 – Tables 53 – Figures 229– Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20819635 "Gel form segment to be the fourth largest growing form during the forecast period." Gel unit dose packaging accounts for roughly 10-15% of the market share. It is widely used in pharmaceuticals for topical gels and ointments, providing...

On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by…

An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical applications comprise proteins such as monoclonal antibodies (mAbs). An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical...

Altri Comunicati